InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Royalty Pharma plc

RPRX Clue Score45
United States Fiscal year ends December CIK 0001802768
$56.93 +1.28% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $56.93 +57.57% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Jun 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2018Revenue1.79Operating income1.36Net income1.38Fiscal year 2019Revenue1.81 +1.1%Operating income2.62Net income2.35 +70.5%Fiscal year 2020Revenue2.12 +17.0%Operating income1.60Net income0.98 −58.5%EPS, diluted1.32Fiscal year 2021Revenue2.29 +7.9%Operating income1.43Net income0.62 −36.4%EPS, diluted1.49 +12.9%Fiscal year 2022Revenue2.24 −2.3%Operating income0.31Net income0.04 −93.1%EPS, diluted0.10 −93.3%Fiscal year 2023Revenue2.35 +5.2%Operating income1.49Net income1.13 +2,549.5%EPS, diluted2.53 +2,430.0%Fiscal year 2024Revenue2.26 −3.9%Operating income1.29Net income0.86 −24.3%EPS, diluted1.91 −24.5%Fiscal year 2025Revenue2.38 +5.1%Operating income1.56Net income0.77 −10.2%EPS, diluted1.78 −6.8%
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 1.79 1.81 2.12 2.29 2.24 2.35 2.26 2.38
Growth +1.1% +17.0% +7.9% −2.3% +5.2% −3.9% +5.1%
Operating income 1.36 2.62 1.60 1.43 0.31 1.49 1.29 1.56
Net income 1.38 2.35 0.98 0.62 0.04 1.13 0.86 0.77
Growth +70.5% −58.5% −36.4% −93.1% +2,549.5% −24.3% −10.2%
EPS, diluted n/a n/a 1.32 1.49 0.10 2.53 1.91 1.78
Growth +12.9% −93.3% +2,430.0% −24.5% −6.8%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2018Operating margin76.0%Net margin76.8%Fiscal year 2019Operating margin144.6%Net margin129.4%Fiscal year 2020Operating margin75.2%Net margin45.9%Fiscal year 2021Operating margin62.5%Net margin27.1%Fiscal year 2022Operating margin13.7%Net margin1.9%Fiscal year 2023Operating margin63.4%Net margin48.2%Fiscal year 2024Operating margin57.1%Net margin37.9%Fiscal year 2025Operating margin65.6%Net margin32.4%
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin 76.0% 144.6% 75.2% 62.5% 13.7% 63.4% 57.1% 65.6%
Net margin 76.8% 129.4% 45.9% 27.1% 1.9% 48.2% 37.9% 32.4%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2018Operating cash flow1.62Buybacks0.00Fiscal year 2019Operating cash flow1.67Buybacks−0.00Fiscal year 2020Operating cash flow2.03Buybacks0.00Fiscal year 2021Operating cash flow2.02Buybacks0.00Fiscal year 2022Operating cash flow2.14Buybacks0.00Fiscal year 2023Operating cash flow2.99Buybacks−0.30Fiscal year 2024Operating cash flow2.77Buybacks−0.23Fiscal year 2025Operating cash flow2.49Buybacks−1.23
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow 1.62 1.67 2.03 2.02 2.14 2.99 2.77 2.49
Buybacks 0.00 −0.00 0.00 0.00 0.00 −0.30 −0.23 −1.23

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2018Cash1.92Shareholders’ equity4.55Fiscal year 2019Cash0.25Total debt6.24Net cash (debt)−5.99Shareholders’ equity6.14Debt to equity1.02Fiscal year 2020Cash1.01Total debt5.82Net cash (debt)−4.81Shareholders’ equity9.90Debt to equity0.59Fiscal year 2021Cash1.54Total debt7.10Net cash (debt)−5.56Shareholders’ equity10.25Debt to equity0.69Fiscal year 2022Cash1.71Total debt7.12Net cash (debt)−5.41Shareholders’ equity9.53Debt to equity0.75Fiscal year 2023Cash0.48Total debt6.14Net cash (debt)−5.66Shareholders’ equity10.08Debt to equity0.61Fiscal year 2024Cash0.93Total debt7.61Net cash (debt)−6.68Shareholders’ equity10.34Debt to equity0.74Fiscal year 2025Cash0.62Total debt8.95Net cash (debt)−8.33Shareholders’ equity9.71Debt to equity0.92
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 1.92 0.25 1.01 1.54 1.71 0.48 0.93 0.62
Total debt n/a 6.24 5.82 7.10 7.12 6.14 7.61 8.95
Net cash (debt) n/a −5.99 −4.81 −5.56 −5.41 −5.66 −6.68 −8.33
Shareholders’ equity 4.55 6.14 9.90 10.25 9.53 10.08 10.34 9.71
Debt to equity n/a 1.02 0.59 0.69 0.75 0.61 0.74 0.92

In billions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In billions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
1.79 1.81 2.12 2.29 2.24 2.35 2.26 2.38
Growth +1.1% +17.0% +7.9% −2.3% +5.2% −3.9% +5.1%
0.39 0.08 0.03 0.20 0.18 0.05 0.00 0.45
0.06 0.10 0.18 0.18 0.23 0.25 0.24 0.57
1.36 2.62 1.60 1.43 0.31 1.49 1.29 1.56
Growth +92.3% −39.2% −10.3% −78.5% +385.9% −13.4% +20.7%
1.52 2.46 1.70 1.24 0.23 1.70 1.33 1.32
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1.38 2.35 0.98 0.62 0.04 1.13 0.86 0.77
Growth +70.5% −58.5% −36.4% −93.1% +2,549.5% −24.3% −10.2%
Per share
n/a n/a 1.32 1.49 0.10 2.54 1.92 1.79
n/a n/a 1.32 1.49 0.10 2.53 1.91 1.78
Growth +12.9% −93.3% +2,430.0% −24.5% −6.8%
n/a n/a 375.4 414.8 438.0 447.6 448.2 429.8
n/a n/a 375.5 414.8 438.0 602.9 594.1 564.5
Growth +10.5% +5.6% +37.7% −1.5% −5.0%

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 2.3% a year over five years, and earnings per share grew 6.2% a year.
  • The diluted share count rose 50.3% in five years, which is dilution.
  • Operating margin is down 9.6 points on five years ago, at 65.6%.
  • Profitable in every one of the 8 years on file.